Does number of dosing sessions and type of adjunctive psychotherapy affect outcomes in psychedelic-assisted-psychotherapy for depressive disorders and anxiety disorders? A systematic review and meta-analysis.
Tomas Lindegaard, Anton Käll
Journal of Affective Disorders February 15, 2026 DOI: 10.1016/j.jad.2025.120732 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Systematic review and meta-analysis Peer reviewed |
|---|---|
| Sample size | 23 |
| Population | Participants in clinical trials of psychedelic-assisted psychotherapy for depressive or anxiety disorders |
| Intervention | Psychedelic-assisted psychotherapy |
| Topics | Anxiety Depression Psychedelic-assisted therapy |
| Keywords | Meta-analysis Psychedelics |
| Key findings | Psychedelic-assisted psychotherapy produced large to very large effects on depression and anxiety symptoms, with some evidence that two dosing sessions may be more effective than one, though this finding was not robust across analyses. |
Abstract
Although there is increasing evidence of the efficacy of psychedelic-assisted psychotherapy (PAP) for depressive and anxiety disorders, less is known regarding how different methodological aspects affect outcomes. This study investigated the moderating impact of one or multiple dosing sessions and type of adjunctive psychotherapy on the efficacy of PAP in depression and anxiety populations. This systematic review and meta-analysis aimed to include all published clinical trials of PAP investigating a primary outcome of symptoms of anxiety disorders or depressive disorders. Adjunctive psychotherapy, operationalized as a dichotomous variable either derived from evidence-based psychotherapy (EBP) or not, and number of dosing sessions were included in the analysis as moderators. Twenty-three studies met inclusion criteria. Results indicated large to very large between and within-group effects of PAP at post-treatment and follow-up, Hedge's g = 0.98-1.83. We found evidence of a moderating effect of the number of dosing sessions in the between-group analysis favoring two sessions over one. This finding was not replicated in the within-group analysis. Only three studies included EBP-derived psychotherapy protocols which limited the possibility of investigating this moderator. Lack of blinded assessment of outcomes and non-adherence to the intention-to-treat principle affected risk of bias negatively. There was some evidence of a moderating effect of two versus one psychedelic dosing session, however this finding needs to be replicated using experimental designs since it was not robust across analyses. The field can be improved by more thorough reporting of psychotherapy protocols to facilitate comparison between studies.
Comparable studies
Other systematic reviews and meta-analyses on anxiety, most cited first.
Citations in the library
Cites 37
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Journal of Psychopharmacology November 30, 2016
- Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Journal of Psychopharmacology November 30, 2016
- Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. The Lancet Psychiatry May 17, 2016
- Trial of Psilocybin versus Escitalopram for Depression New England Journal of Medicine April 14, 2021
- Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder JAMA Psychiatry November 4, 2020
and 32 more in the library